Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DAG87H
|
|||
| Drug Name |
Enfortumab vedotin
|
|||
| Synonyms |
Padcev
Click to Show/Hide
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Urothelial carcinoma [ICD-11: 2C92.0] | Approved | [1] | |
| Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 3 | [2] | ||
| Company |
Astellas
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nectin cell adhesion molecule 4 (NECTIN4) | Target Info | . | [3] |
| KEGG Pathway | Adherens junction | |||
| Reactome | Adherens junctions interactions | |||
| WikiPathways | Cell junction organization | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. | |||
| REF 2 | ClinicalTrials.gov (NCT03474107) An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301). U.S.National Institutes of Health. | |||
| REF 3 | Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022 Mar;72(2):165-182. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.